The Real Story of TILT stock price and why ready to moveA few highlights from the Q2 earnings report and an understanding that the only reason stock is being pushed down is due to financing negotiations.
The company is growing at 13% per quarter to $39 million - with July reported $15 million revenue growth and positive EBITDA – exactly as per strategy.
Some things coming in Q3 and Q4
- The large focus in Q2 was on our operations and worked towards building a profitable business model – therefore creating a solid foundation for growth. This is what was successfully achieved.
Gross profit grew 240% Gross margin grew 24.5%. AND JULY HAD POSITIVE EBITDA
- efforts to find attractive sources of capital was made easier as moved closer to positive EBITDA
Due diligence has now been completed and the negotiation of definitive documents. My guess these folks are the reason stock is being artificially pushed down until deal closes.
- TILT has a presence in every state with a legal program, as well as all states with CBD markets, along with seven additional countries across four continents supporting well over 1,500 brands
- Our plant cultivation retail businesses in the limited license market of Massachusetts experienced tremendous progress in Q2. These efforts resulted in 400% month-over-month growth in wholesale revenue in July. Still 2 retail licenses to come. an additional 50,000 square feet of cultivation and production space, bringing our total footprint to 117,000 square feet at this property.
- able to fully integrator our software platform Baker into our recently acquired distribution asset Blackbird, creating a technology powerhouse with more than 2 million users
- Jupiter Research had a very productive second quarter which shipments more than doubling from the prior year
- Sale of disposable devices are up 150% year-over-year, spurred by demand from the rapidly increasing CBD market. While revenue has more than doubled, we have also seen significant improvement in EBITDA and margins at Jupiter.
- Our Powell River facility has been on hold, but it is currently 95% complete and simply awaiting license share. Our focus with this facility is on the processing of cannabis as we see the Canadian market opening up to value added products later this year, where we would be able to integrate our consumer product asset Jupiter, just as we have in Pennsylvania.
- We are currently shipping products into new markets such as Mexico, Chile, Colombia, New Zealand, South Africa and multiple countries throughout Europe. We are particularly excited about our opportunity in Canada, where the opening of the adult-use extracts market later this calendar year creates a significant opportunity for us. Jupiter has orders from four of the top 15 license producers in Canada with others looking to place initial orders in the near term.